Here are the 10-Q quarterly reports from Bioscience Health Innov (BHIC) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow BHIC and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full BHIC filings page.
BioScience Health Innovations Inc., a Nevada-based wellness products company, reported weaker results for the quarter and six months ended June 30, 2026. Six‑month revenues fell to $1,787,310 from $2,984,533 a year earlier, and the company swung to a net loss of $415,660 versus prior‑year net income of $884,502. For the quarter, revenue declined to $1,036,364 and the company posted a net loss of $185,753.
Operations used $1,093,981 of cash in the first half, driven by higher inventory, lower deferred revenue, and the loss. Liquidity was supported by a cash balance of $712,378, working capital of $1,685,704, and $773,271 raised from common stock sales. The company also converted related‑party advances into a $260,402 note payable at 7% interest. Management highlights a patent‑pending Mods Max delivery system, an expanding patent portfolio, and preparation for a senior‑exchange uplisting, including a completed $1.00 Regulation A round and an amended offering at $4.50 per share. However, disclosure controls and internal control over financial reporting were deemed ineffective due to material weaknesses in staffing, segregation of duties, governance, and documentation.
BioScience Health Innovations Inc. reported a net loss of $229,907 for the three months ended March 31, 2026, compared with net income of $426,798 a year earlier. Revenue fell to $750,946 from $1,227,070, as the company shifted sales channels, brought in a new Amazon distributor, and saw a major co-brand order slip into the second quarter.
Operating costs climbed sharply, with general and administrative expenses rising to $625,809 and consulting fees to $89,694, partly tied to efforts to move from the OTC market to a senior exchange and to system upgrades. Despite the loss, cash increased to $1,145,005 and net working capital reached $1,549,089, helped by $437,067 from common stock issuance and related-party financing, including a new $460,402 note payable at 7%.
Management highlights a growing portfolio of patent-pending mitochondrial and mental-health products and believes current liquidity is sufficient for the next year. However, disclosure controls and internal control over financial reporting were deemed ineffective due to limited accounting resources, lack of segregation of duties, and absence of an independent board or audit committee.
BioScience Health Innovations (BHIC) filed its quarterly report for the period ended September 30, 2025. The company posted strong year-to-date results, with revenue of $4,115,960 and net income of $875,720, compared with $1,234,744 and $77,043 a year earlier. In Q3, revenue was $1,131,427 and the company recorded a small net loss of $8,782 as operating expenses rose with growth.
Cash was $1,139,423, inventory increased to $757,500, and total assets reached $2,067,100. Current liabilities were $356,140, including $228,298 due to related parties. Operating cash flow was positive at $272,874. The company expanded authorized common stock to 250,000,000 and executed a 1‑for‑4 reverse split; 10,979,055 common shares were outstanding as of October 24, 2025. There are 140,000 Series A preferred shares outstanding, each convertible into three common shares subject to a 4.99% beneficial ownership limit.
Management disclosed material weaknesses in internal controls and noted substantial doubt about the company’s ability to continue as a going concern due to historical losses and reliance on related-party advances, despite improved year-to-date profitability.